Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials
2016 ◽
Vol 36
(8)
◽
pp. 1077-1087
◽
2018 ◽
Vol 37
(10)
◽
pp. 2611-2620
◽
2015 ◽
Vol 128
(12)
◽
pp. 1367-1373.e1
◽
2018 ◽
Vol 17
(3)
◽
pp. 215-225
◽